Lynas Rare Earths Shares Surge as Quarterly Revenue Jumps on Strong Prices 
Sanofi Reports Positive Late-Stage Results for Amlitelimab in Eczema Treatment 
Nintendo Stock Jumps as Switch 2 Becomes Best-Selling Console in the U.S. in 2025 
Baidu Shares Surge After Official Launch of Advanced Ernie 5.0 AI Model 
Trump Signs Executive Order to Limit Wall Street Investment in Single-Family Homes 
ByteDance Finalizes Majority U.S.-Owned TikTok Joint Venture to Avert American Ban 
Memory Chip Shortage Drives Higher Gadget Prices and Weakens Global Tech Demand 
Nvidia CEO Jensen Huang Plans China Visit Amid AI Chip Market Uncertainty 
Apple Stock Jumps as Company Prepares Major Siri AI Chatbot Upgrade 
FAA Says It Is Not Blocking Boeing 737 MAX 7 and MAX 10 Certification 
Morgan Stanley Flags High Volatility Ahead for Tesla Stock on Robotaxi and AI Updates 
OpenAI Launches Stargate Community Plan to Offset Energy Costs and Support Local Power Infrastructure 
Microsoft Restores Microsoft 365 Services After Widespread Outage 
BitGo IPO Prices Above Range, Raises $212.8M in Landmark Crypto Market Debut 
Netflix Stock Slips After Earnings as Soft 2026 Guidance Overshadows Subscriber Milestone 
Intel Stock Slides Despite Earnings Beat as Weak Q1 Outlook Raises Concerns 
Global DRAM Chip Shortage Puts Automakers Under New Cost and Supply Pressure 
Zug, Switzerland, May 4, 2017 - Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology, today announced that it will report its financial results for the first quarter of 2017 on Thursday, May 11, 2017. Following the announcement, Auris Medical's management team will host a live conference call and webcast at 8:00 am Eastern Time (2:00 pm Central European Time) to discuss the Company's financial results and to provide a general business update.
To participate in this conference call, dial 1-877-280-3459 (USA) or +1-646-254-3374 (International), and enter passcode 5733572. A live webcast of the conference call can be accessed on the Investor Relations section of the Auris Medical website at www.aurismedical.com. A replay will be available approximately two hours following the live call.
About Auris Medical
Auris Medical is a Swiss biopharmaceutical company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology. The Company is focused on the Phase 3 development of treatments for acute inner ear hearing loss (AM-111) and for acute inner ear tinnitus (Keyzilen®; AM-101) by way of intratympanic administration with biocompatible gel formulations. In addition, Auris Medical is pursuing intranasal betahistine for Meniere's disease and vestibular vertigo (AM-125) as well as early-stage research and development projects. The Company was founded in 2003 and is headquartered in Zug, Switzerland. The shares of Auris Medical Holding AG trade on the NASDAQ Global Market under the symbol "EARS."
Contact: Cindy McGee, Head of Investor Relations and Corporate Communications, +41 61 201 1350, [email protected]
